Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15714MR)

This product GTTS-WQ15714MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15714MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5502MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ15952MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ15711MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ6096MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ7233MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ13279MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ3646MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ12432MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NI-0501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW